Blog

Enhancing PD-L1 Stability: The Role of EZH2 InhibitionIn recent years, the role of PD-L1 (Programmed Death-Ligand 1) in cancer immunotherapy has garnered significant attention, particularly regarding its expression and stability. This study, led by Seán Mac Fhearraigh, PhD, investigates how inhibiting EZH2 (Enhancer of Zeste Homolog 2) enhances PD-L1 protein stability, with the deubiquitinase USP22 (ubiquitin-specific peptidase 22) identified as a key regulator in this process. The findings provide valuable insights into potential therapeutic strategies for improving cancer treatment outcomes.Study SummaryThe research highlights a novel interaction between EZH2 inhibition and PD-L1 expressio …